Indegene IPO Analysis @ Chanakyanipothi.com,
the Oldest & the most Trusted Investment website in India. Operational since 8th December 1999, this is the Only Investment website in India, which has successfully completed 23 Years

 

Indegene IPO Promoters
The company is professionally managed company and does not have an identifiable promoter

Indegene: Company Details

INDEGENE is a “digital-first” commercialization company focused exclusively on the global life sciences industry. Its solutions enable biopharmaceutical, emerging biotech and medical devices companies develop products, launch them in the market, and drive sales through their life cycle in a more effective, efficient and modern manner. It achieves this by combining over two decades of healthcare domain expertise and fit-for-purpose technology. Its portfolio of solutions covers all aspects of
commercial, medical, regulatory and R&D operations of life sciences companies.
The company has established client relationships with 19 of the 20 largest biopharmaceutical companies in the world by revenue for the Financial Year 202, having earned more than 70.00% of its total revenue from continuing operations for each of the Financial Years 2022, 2021 and 2020 from these 19 customers. As of June 30, 2022, it had a total of 52 active clients (i.e., clients from whom we earned US$0.25 million or more in revenues during the 12 months preceding the relevant
date). It had 21 clients from whom it earned between US$1 million and US$10 million in revenues, three clients from whom it earned between US$10 million and US$25 million in revenues, and four clients from whom it earned more than US$25 million in revenues, during the 12 months ended June 30, 2022.

Life sciences enterprises require a talent pool with in-depth domain expertise on the journey of a drug or medical device from the research lab to the market to organize and analyze scientific and clinical data, navigate the regulatory landscape and the ethical guidelines within which the industry operates, and to develop the requisite medical content for healthcare professionals, patients, and payers. Scarcity of such talent is a major hindrance in operations. At the same time, drug pricing caps create margin
pressures on biopharmaceutical companies, thus risking the overall profitability of the industry and consequently, operations spend. While there are such talent gaps and margin pressures, life sciences companies are placing greater emphasis on digital innovation and enterprise-wide transformation initiatives to improve operational efficiencies. The growing maturity of technology tools is also leading to requirements of domain-centric digital expertise. Life sciences companies are embracing technological partners with the requisite domain expertise to aid them in this digital journey, and this is where our role lies.
Positioned at the intersection of healthcare and technology, its solutions span across different stages of the commercialization lifecycle of drugs and medical devices. Its Enterprise Commercial Solutions and our Omnichannel Activation solutions cater to the commercial functions of life sciences companies while its Enterprise Medical Solutions and Enterprise Clinical Solutions cater to their medical and R&D functions.
For more information, click 

Objects of the IPO
The Company proposes to utilize the Net Proceeds towards funding of the following objects:
1. Repayment/prepayment of indebtedness of one of its Subsidiaries, ILSL Holdings, Inc.;
2. Funding the capital expenditure requirements of the Company and our Material Subsidiary, Indegene, Inc.;
3. Payment of consideration towards acquisition of additional shares in DT Associates Limited by ILSL
Holdings, Inc., a Subsidiary.

 

Go to SME IPOs Section: Click